Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma

Video

In Partnership With:

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma (MCC).

More than two-thirds of patients with MCC have disease caused by the Merkel cell polyomavirus. These patients have a very low tumor mutational burden (TMB), Nghiem says. The remaining third, which have disease caused by ultraviolet light, have an extremely high TMB. Nghiem says this is interesting because the efficacy of immunotherapy appears to be very similar between the 2 groups.

The dichotomy of causes does not yet seem to signal a difference in response to immunotherapy, Nghiem explains, and patients with both virally-mediated MCC and MCC as a result of sun exposure, can be very immunogenic. There is still a lot to learn, Nghiem adds, as about 50% of all patients with MCC do not respond to immunotherapy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,